Xenon Pharmaceuticals Inc.
196 articles about Xenon Pharmaceuticals Inc.
-
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
10/9/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurology has published peer-reviewed efficacy and safety results from the X-TOLE Phase 2b randomized clinical trial of XEN1101, a novel potassium channel opener, in adults with focal epilepsy.
-
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
10/6/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Jefferies Inaugural Biotech CNS/Neuro Summit to be held on October 11, 2023.
-
Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
9/14/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on September 20, 2023.
-
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
9/12/2023
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced that the company will host an investor webinar with two leading key opinion leaders focused on major depressive disorder.
-
Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
9/4/2023
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced a summary of its oral and poster presentations at the 35th International Epilepsy Congress taking place in Dublin, Ireland from September 2-6, 2023.
-
Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
8/31/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Wells Fargo 2023 Healthcare Conference to be held September 6-8, 2023.
-
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/9/2023
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
-
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
8/8/2023
Xenon Pharmaceuticals Inc. announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover. Dr. Cannon has more than 30 years of experience in the pharmaceutical industry, where she served in business and commercial leadership roles at Merck and Co., UCB, Otsuka and Roivant.
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update
8/2/2023
Xenon Pharmaceuticals Inc. announced it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, August 9, 2023.
-
Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
6/6/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.
-
Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference
5/31/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2023 Jefferies Healthcare Conference taking place June 7-9, 2023 in New York, NY.
-
Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference
5/11/2023
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced that the company will present at the 2023 RBC Capital Markets Global Healthcare Conference taking place May 16-17, 2023 in New York, NY.
-
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/9/2023
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
-
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
5/3/2023
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced that the company will present at the BofA Securities Health Care Conference 2023 taking place May 9-11, 2023.
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
5/2/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets on Tuesday, May 9, 2023.
-
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
4/24/2023
Xenon Pharmaceuticals Inc. today announced its upcoming oral and poster presentations at the 2023 American Academy of Neurology (AAN) Annual Meeting in Boston, MA.
-
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
4/21/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will host a company presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference to be held in Toronto, Ontario from April 25-26, 2023.
-
Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
4/18/2023
Xenon Pharmaceuticals Inc. today announced that the company will present at the 22nd Annual Needham Virtual Healthcare Conference taking place April 17-20, 2023.
-
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
3/22/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual Stifel 2023 CNS Days taking place March 28-29, 2023.
-
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/1/2023
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.